Recombinant SATB2 anticorps (AA 200-300)

N° du produit ABIN7871951

Cet anticorps Lapin Monoclonal détecte spécifiquement SATB2 dans IHC (p). Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Recombinant SATB2 anticorps (AA 200-300) (ABIN7871951)

Antigène: SATB2 (SATB Homeobox 2 (SATB2))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp SATB2 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: SATB2-8697R

Détail du produit anti-SATB2 anticorps

Épitope: AA 200-300

Fonction: SATB2 Antibody

Purification: Protein A/G affinity

Immunogène: A synthetic peptide corresponding to human SATB2 protein (within amino acids 200-300) was used as the immunogen for the SATB2 antibody.

Isotype: IgG, kappa

Information d'application

Indications d'application: Optimal dilution of the SATB2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the SATB2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur SATB2

Antigène: SATB2 (SATB Homeobox 2 (SATB2))

Autre désignation: SATB2

Sujet: SATB2 is a DNA binding protein that specifically binds nuclear matrix attachment regions. It is involved in transcription regulation and chromatin remodeling. SATB2 expression in colorectal carcinomas (CRC) is correlated with good prognosis and in laryngeal squamous cell carcinoma it functions as a tumor suppressor wherein loss of expression is positively correlated with high tumor grade and recurrence. Moreover, SATB2, in combination with CK20, could identify almost all CRC s. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2. Additionally, SATB2 antibody can identify neuroendocrine neoplasms of colon and rectum because SATB2 is usually negative in neuroendocrine neoplasms of the GI tract, pancreas, and lung. More recently, it has been reported that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.

UniProt: Q9UPW6